New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2023, Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders, [3rd ed.].
View latest version (2023)Bibliographic Info
GuidelineUpdate of the Mental Health Gap Action Programme (mhGAP) guidelines for mental, neurological and substance use disorders, 2015
Year of Publication2015
Issuing InstitutionWorld Health Organization
Recommendation
Status
Retired
Recommended in favor
Conditional
Certainty of evidence
Low
(Psychosis including schizophrenia and bipolar disorder) Second-generation antipsychotics (with the exception of clozapine which is indicated for treatment resistant psychosis) can be offered for the treatment of psychotic disorders (including schizophrenia). There is no clinically relevant advantage of one second-generation antipsychotic over others and choice should be based on availability, cost, patient preferences and possible adverse effects associated with each medication.